

UPDATE ON FIFTH LETTER FROM SAC CAPITAL PRIVATE LIMITED

1. INTRODUCTION

The board of directors (the "**Board**") of Cordlife Group Limited (the "**Company**") refers to its announcement dated 24 May 2024 in relation to, among others, the letters dated (a) 23 February 2024 (the "**First SAC Letter**"), (b) 22 March 2024 (the "**Second SAC Letter**"), (c) 22 April 2024 (the "**Third SAC Letter**") and (d) 23 May 2024 (the "**Fourth SAC Letter**") sent by SAC Capital Private Limited ("**SAC Capital**") for and on behalf of Nanjing Xinjiekou Department Store Co., Ltd. ("**NJXJK**") to the Company (the "**24 May 2024 Announcement**").

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as in the 24 May 2024 Announcement.

2. FIFTH LETTER FROM SAC CAPITAL

The Board wishes to update the shareholders of the Company ("**Shareholders**") that it has on 24 June 2024 received a letter (the "**Fifth SAC Letter**" and together with the First SAC Letter, the Second SAC Letter, the Third SAC Letter, and the Fourth SAC Letter, the "**SAC Letters**") dated 21 June 2024 from SAC Capital for and on behalf of NJXJK stating, among others, that:

- (a) since the date of the Fourth SAC Letter, it is noted that:
- (i) the Company announced on 28 May 2024, *inter alia*, that the Ministry of Health ("**MOH**") had on 27 May 2024 issued a further notice to the Company to stop the collection, testing, processing and/or storage of any new cord blood for up to an additional three months with effect on and from 15 June 2024 or unless sooner approved by the Director-General of Health (the "**Second Notice**"); and
 - (ii) the Company announced on 18 June 2024, *inter alia*, that the MOH has considered the Company's response to the Second Notice and has directed the Company to give effect to the contents of the Second Notice with effect on and from 15 June 2024;
- (b) SAC Capital has been instructed to inform the Company that:
- (i) together with NJXJK, SAC Capital has been and will continue to closely monitor and assess developments relating to the Company, in particular, the above recent development relating to the Second Notice, including any further potential financial impact of the extended suspension of operations (pursuant to the Second Notice) on the financial performance of the Company and its subsidiaries for the current financial year and the Company's progress to fulfil the relevant requirements and receive the MOH's approval to resume operations as soon as possible; and

- (ii) as of the date of the Fifth SAC Letter, NJXJK is still considering making the Potential Offer, and SAC Capital is furthering the discussions with NJXJK on the terms of the Potential Offer, taking into account the above and any other developments relating to the Company which are or may be material to NJXJK's consideration of the Potential Offer;
- (c) nothing in the Fifth SAC Letter shall be construed as NJXJK having a firm intention to make an offer for shares in the Company under the Singapore Code on Take-overs and Mergers ("**Code**"); and
- (d) NJXJK will inform the Company of any material update on the foregoing and in the meantime, NJXJK wishes to highlight, for the attention of the Board, Rule 5 of the Code.

The Company will, in compliance with applicable laws and regulations, including but not limited to the requirements of the Listing Manual of the Singapore Exchange Securities Trading Limited, make the appropriate announcements on SGXNET in the event of any material developments.

In the meantime, Shareholders and potential investors should exercise caution when dealing in the shares of the Company. In particular, there is no certainty or assurance that the Potential Offer will be made or that any transaction will materialise as a result of the SAC Letters. They should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

The directors of the Company (including any director who may have delegated detailed supervision of this Announcement) have taken all reasonable care to ensure that the facts stated and opinions expressed in this Announcement are fair and accurate and that there are no other material facts not contained in this Announcement, the omission of which would make any statement in this Announcement misleading. The directors of the Company jointly and severally accept responsibility accordingly.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Ivan Yiu Pang Fai
Group CEO

25 June 2024